Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
5(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
10%
Ph phase_1
5
50%
Ph early_phase_1
1
10%
Ph phase_2
3
30%

Phase Distribution

6

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(4)

Detailed Status

Completed4
Recruiting4
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 15 (50.0%)
Phase 23 (30.0%)
Phase 31 (10.0%)

Trials by Status

completed440%
not_yet_recruiting110%
active_not_recruiting110%
recruiting440%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825
not_yet_recruitingphase_3

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500
recruitingphase_1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

NCT06364410
completedphase_1

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

NCT05198804
completedphase_2

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

NCT04814108
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05128825Phase 2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
NCT07546500Phase 3

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Not Yet Recruiting
NCT06364410Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Recruiting
NCT05198804Phase 1

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Completed
NCT04814108Phase 2

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Completed
NCT04833582Phase 1

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Completed
NCT04158336Phase 1

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Completed
NCT06369155Phase 2

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Recruiting
NCT04005690Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
NCT06351332Phase 1

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Active Not Recruiting

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10